Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy
Multidrug resistance protein 2 (MRP2), encoded by the ATP-binding cassette C2 (ABCC2) gene, is an efflux pump located on the apical membrane of many polarized cells, which transports conjugate compounds by an ATP-dependent mechanism. The correlation of G1249A ABCC2 polymorphism with the development...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Spandidos Publications
2013
|
Online Access: | http://psasir.upm.edu.my/id/eprint/29782/1/Multidrug%20resistance%20protein%202%20genetic%20polymorphism%20and%20colorectal%20cancer%20recurrence%20in%20patients%20receiving%20adjuvant%20FOLFOX.docx |
_version_ | 1796971609471320064 |
---|---|
author | Mirakhorli, Mojgan Abdul Rahman, Sabariah Abdullah, Syahrilnizam Vakili, Masoud Rozafzon, Reza Khoshzaban, Ahad |
author_facet | Mirakhorli, Mojgan Abdul Rahman, Sabariah Abdullah, Syahrilnizam Vakili, Masoud Rozafzon, Reza Khoshzaban, Ahad |
author_sort | Mirakhorli, Mojgan |
collection | UPM |
description | Multidrug resistance protein 2 (MRP2), encoded by the ATP-binding cassette C2 (ABCC2) gene, is an efflux pump located on the apical membrane of many polarized cells, which transports conjugate compounds by an ATP-dependent mechanism. The correlation of G1249A ABCC2 polymorphism with the development of colorectal cancer (CRC) and poor prognosis was evaluated in patients who were treated with fluorouracil/leucovorin (FL) plus oxaliplatin (FOLFOX-4). A total of 50 paraffin embedded tissue samples collected from CRC patients were analyzed to identify the polymorphism. Patients were in stage II/III and received postoperative FOLFOX-4 chemotherapy. As a control group, an equal number of unrelated healthy subjects were enrolled in the study. The polymorphism was genotyped by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, and results were compared with clinicopathological markers, early relapse and survival rates. During the 12 months of follow-up, local and distant recurrences were observed in 15 (30%) patients. No significant difference in the distribution of wild-type and polymorphic genotypes was observed between the patient and control groups and between the patients who experienced recurrence within 1 year and those who did not (all P>0.05). In conclusion, the G1249A polymorphism is not associated with CRC risk and early recurrence. However, significant correlation was observed between G1249A polymorphism and the overall survival and disease-free survival of the patients. |
first_indexed | 2024-03-06T08:15:32Z |
format | Article |
id | upm.eprints-29782 |
institution | Universiti Putra Malaysia |
language | English |
last_indexed | 2024-03-06T08:15:32Z |
publishDate | 2013 |
publisher | Spandidos Publications |
record_format | dspace |
spelling | upm.eprints-297822015-10-07T08:27:42Z http://psasir.upm.edu.my/id/eprint/29782/ Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy Mirakhorli, Mojgan Abdul Rahman, Sabariah Abdullah, Syahrilnizam Vakili, Masoud Rozafzon, Reza Khoshzaban, Ahad Multidrug resistance protein 2 (MRP2), encoded by the ATP-binding cassette C2 (ABCC2) gene, is an efflux pump located on the apical membrane of many polarized cells, which transports conjugate compounds by an ATP-dependent mechanism. The correlation of G1249A ABCC2 polymorphism with the development of colorectal cancer (CRC) and poor prognosis was evaluated in patients who were treated with fluorouracil/leucovorin (FL) plus oxaliplatin (FOLFOX-4). A total of 50 paraffin embedded tissue samples collected from CRC patients were analyzed to identify the polymorphism. Patients were in stage II/III and received postoperative FOLFOX-4 chemotherapy. As a control group, an equal number of unrelated healthy subjects were enrolled in the study. The polymorphism was genotyped by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, and results were compared with clinicopathological markers, early relapse and survival rates. During the 12 months of follow-up, local and distant recurrences were observed in 15 (30%) patients. No significant difference in the distribution of wild-type and polymorphic genotypes was observed between the patient and control groups and between the patients who experienced recurrence within 1 year and those who did not (all P>0.05). In conclusion, the G1249A polymorphism is not associated with CRC risk and early recurrence. However, significant correlation was observed between G1249A polymorphism and the overall survival and disease-free survival of the patients. Spandidos Publications 2013-02 Article PeerReviewed application/msword en http://psasir.upm.edu.my/id/eprint/29782/1/Multidrug%20resistance%20protein%202%20genetic%20polymorphism%20and%20colorectal%20cancer%20recurrence%20in%20patients%20receiving%20adjuvant%20FOLFOX.docx Mirakhorli, Mojgan and Abdul Rahman, Sabariah and Abdullah, Syahrilnizam and Vakili, Masoud and Rozafzon, Reza and Khoshzaban, Ahad (2013) Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy. Molecular Medicine Reports, 7 (2). pp. 613-617. ISSN 1791-2997; ESSN: 1791-3004 |
spellingShingle | Mirakhorli, Mojgan Abdul Rahman, Sabariah Abdullah, Syahrilnizam Vakili, Masoud Rozafzon, Reza Khoshzaban, Ahad Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy |
title | Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy |
title_full | Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy |
title_fullStr | Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy |
title_full_unstemmed | Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy |
title_short | Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy |
title_sort | multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant folfox 4 chemotherapy |
url | http://psasir.upm.edu.my/id/eprint/29782/1/Multidrug%20resistance%20protein%202%20genetic%20polymorphism%20and%20colorectal%20cancer%20recurrence%20in%20patients%20receiving%20adjuvant%20FOLFOX.docx |
work_keys_str_mv | AT mirakhorlimojgan multidrugresistanceprotein2geneticpolymorphismandcolorectalcancerrecurrenceinpatientsreceivingadjuvantfolfox4chemotherapy AT abdulrahmansabariah multidrugresistanceprotein2geneticpolymorphismandcolorectalcancerrecurrenceinpatientsreceivingadjuvantfolfox4chemotherapy AT abdullahsyahrilnizam multidrugresistanceprotein2geneticpolymorphismandcolorectalcancerrecurrenceinpatientsreceivingadjuvantfolfox4chemotherapy AT vakilimasoud multidrugresistanceprotein2geneticpolymorphismandcolorectalcancerrecurrenceinpatientsreceivingadjuvantfolfox4chemotherapy AT rozafzonreza multidrugresistanceprotein2geneticpolymorphismandcolorectalcancerrecurrenceinpatientsreceivingadjuvantfolfox4chemotherapy AT khoshzabanahad multidrugresistanceprotein2geneticpolymorphismandcolorectalcancerrecurrenceinpatientsreceivingadjuvantfolfox4chemotherapy |